| 摘要: |
| 目的：评价（3+PRN）方案的玻璃体腔注射雷珠单抗治疗缺血性或非缺血性视网膜分支静脉阻塞（BRVO）相关黄斑水肿（ME）的疗效及安全性。方法：回顾性、连续、病例对照研究。纳入由临床确诊的66例(66眼)BRVO继发ME患者，根据荧光造影分为非缺血BRVO组46例（46眼）和缺血性BRVO组20例（20眼），所有患者均采用3+RPN的玻璃体腔注射雷珠单抗方案治疗，观察两组患者治疗后1个月、3个月及6个月的最佳矫正视力（BCVA）、黄斑中心凹视网膜厚度（CMT）的变化以及两组患者IVR注射频率差异。结果：非缺血性BRVO组基线、治疗后1个月、3个月、6个月时BCVA为0.56±0.17、0.21±0.13、0.21±0.07、0.2±0.08；缺血性BRVO组的分别为0.61±0.23、0.27±0.18、0.26±0.18、0.23±0.09。非缺血性BRVO组基线、治疗后1个月、3个月、6个月时CMT为553±182.05μm、275.87±68.33μm、250.17±35.77μm、246.35±23.38μm；缺血性BRVO组的分别为608.8±211.29μm、310.08±93.64μm、263.45±56.29μm、269.4±90.26μm。在两组中，治疗后第1、3和6个月的平均BCV A及CMT值与基线时的平均BCVA和CMT值组内比较，差异均有统计学意义(p<0.05)。两组组间的基线和治疗后第1、3、6个月的的BCVA和平均CMT差异均无统计学意义(p>0.05)。非缺血组和缺血组6个月中的平均注射频率分别为(4.17±0.93)次和(4.45±0.69)次，两组差异无统计学意义(p>0.05)。结论：采用（3+PRN）玻璃体腔内注射雷珠单抗方案是治疗缺血性和非缺血性BRVO相关ME的一种安全有效的方法，并且达到了相似功能和解剖改善。 |
| 关键词: 视网膜分支静脉阻塞、黄斑水肿、雷珠单抗 |
| DOI： |
| 分类号: |
| 基金项目: |
|
| Intravitreal injection of ranibizumab in the treatment of macular edema due to branch retinal vein occlusion |
|
Mei-Dan Wen.,he xiao juan
|
|
Nanxishan Hospital of Guangxi Zhuang Autonomous Region
|
| Abstract: |
| Objective: to evaluate the efficacy and safety of intravitreal injection of ranibizumab (3+PRN) in the treatment of ischemic or non-ischemicdue branch retinal vein occlusion(BRVO) secondary to macular edema(ME) . Methods: a retrospective, continuous, case-control study. A total of 33 patients (66 eyes) with BRVO secondary to ME were divided into non-ischemic BRVO group (46 eyes) and ischemic BRVO group (20 eyes) by fundus fluorescein angiography. All patients were treated with 3+RPN intravitreal injection of ranibizumab. The changes of best-corrected visual acuity (BCVA) and central macular thickness (CMT) and the difference of IVR injection frequency between the two groups were observed at 1 month, 3 months and 6 months after treatment. Results: The BCVA at baseline, 1 month, 3 months and 6 months after treatment in non-ischemic BRVO group were 0.56 ±0.17,0.21 ±0.13,0.21 ±0.07 and 0.2 ±0.08, while those in ischemic BRVO group were 0.61±0.23、0.27±0.18、0.26±0.18 and 0.23±0.09, respectively. The CMT at baseline, 1 month, 3 months and 6 months after treatment in non-ischemic BRVO group were553±182.05μm、275.87±68.33μm、250.17±35.77μm and 246.35±23.38μm, while those in ischemic BRVO group were 608.8±211.29μm、310.08±93.64μm、263.45±56.29μm and 269.4±90.26μm, respectively. In the two groups, the average BCVA and CMT at the 1st, 3rd and 6th month were significantly different from those at the baseline (p < 0.05). There was no significant difference in BCVA and average CMT between the two groups at baseline and at the 1st, 3rd and 6th month. The average injection frequency in 6 months in non-ischemic group and ischemic group was (4.17 ±0.93) and (4.45±0.69) respectively, and there was no significant difference between the two groups (p > 0.05). Conclusion: intravitreal injection of ranibizumab (3+PRN) is a safe and effective method for the treatment of ischemic and non-ischemic BRVO secondary to ME with similar function and anatomical improvement. |
| Key words: Branch retinal vein occlusion macular edema ranibizumab |
